Can we develop effective disease-modifying therapies for Spinocerebellar Ataxias (SCAs) by targeting polyglutamine expansion toxicity and enhancing autophagic clearance of mutant protein aggregates?
...
Research Question
Mermaid diagram (expand to render)
Can we develop effective disease-modifying therapies for Spinocerebellar Ataxias (SCAs) by targeting polyglutamine expansion toxicity and enhancing autophagic clearance of mutant protein aggregates?
Gap Addressed
Addresses the critical lack of disease-modifying treatments for SCAs, which are progressive neurodegenerative disorders causing cerebellar degeneration and severe motor impairment.
Background
Spinocerebellar ataxias are a heterogeneous group of autosomal dominant disorders characterized by progressive cerebellar ataxia, often caused by CAG repeat expansions encoding polyglutamine (polyQ) tracts in various proteins:
SCA1: ATXN1 gene (CAG repeat in encoded protein)
SCA2: ATXN2 gene (CAG repeat)
SCA3/MJD: ATXN3 gene (CAG repeat) — most common worldwide
SCA6: CACNA1A gene (CAG repeat)
SCA7: ATXN7 gene (CAG repeat)
Current treatments are only symptomatic (e.g., riluzole, amantadine) and do not modify disease progression.
Experimental Design
Approach 1: PolyQ Toxicity Mechanism Elucidation
Define the molecular mechanisms by which expanded polyQ proteins cause neuronal dysfunction.
Model System
In vitro: Induced pluripotent stem cells (iPSCs) from SCA1, SCA2, SCA3, SCA6 patients, differentiated into cerebellar neurons
In vivo: Mouse models for SCA1 (ATXN1[82Q] knock-in) and SCA3 (MJD1.92 transgenic)
Cell lines: HEK293T for protein interaction studies
Validation Protocol
Characterization: Verify mutant protein expression, aggregate formation, and cellular phenotypes
Mechanism studies:
Transcriptomic profiling (RNA-seq) to identify dysregulated pathways
Proteomic analysis of aggregate composition
Mitochondrial function assays
Autophagy flux measurements
3. Intervention testing: Test candidate compounds for aggregate reduction and function restoration
Expected Outcomes
Identify 2-3 key pathways driving polyQ toxicity in cerebellar neurons
Establish scalable iPSC-based drug screening platform
Identify compounds that reduce mutant protein levels by >50%
Approach 2: Autophagy Enhancement Screening
High-throughput screening for compounds that enhance autophagic clearance of mutant polyQ proteins.
Design
| Parameter | Specification | |-----------|---------------| | Primary screen | 5,000+ compounds (FDA-approved library) | | Secondary validation | Top 100 hits in iPSC-derived neurons | | Tertiary in vivo | Top 10 compounds in SCA mouse models | | Readout | Mutant protein level, aggregate burden, behavioral improvement |
Compound Classes to Test
mTOR inhibitors (rapamycin, Torin1)
Autophagy inducers (carbamazepine, tamoxifen)
HSP90 inhibitors (geldanamycin analogs)
Histone deacetylase (HDAC) inhibitors
Novel autophagy-enhancing small molecules
Outcome Measures
| Measure | Target | |---------|--------| | Pathway identification | 2-3 novel targets validated | | Primary screen hits | >50 compounds with >50% aggregate reduction | | In vivo efficacy | >30% mutant protein reduction in mouse brain | | Behavioral rescue | Significant improvement in rotarod/grid tests |
Feasibility Assessment
Technical Requirements
Available: iPSC lines from multiple SCA subtypes exist; mouse models available
Required: High-throughput screening facility, medicinal chemistry support
Manageable: Cerebellar neuron differentiation protocols established
Resource Needs
| Resource | Estimated Cost | |----------|----------------| | iPSC culture and differentiation | $300,000 | | High-throughput screening | $200,000 | | In vivo mouse studies | $400,000 | | Target validation | $200,000 | | Total | $1,100,000 |
Timeline
Year 1: iPSC characterization and assay development
Year 1-2: Primary and secondary screening
Year 2-3: In vivo validation
Year 3-4: IND-enabling studies for lead compound
Scientific Value
Score: 8/10
SCAs are monogenic, providing clean genetic model for polyQ toxicity
Understanding common mechanisms may benefit all polyQ diseases (HD, SCA, SBMA)
Cerebellar degeneration mechanism has broader implications
Disease Impact
Score: 9/10
SCAs affect 1 in 50,000 globally; no disease-modifying treatments exist
Progressive disability leads to severe quality of life impairment
Early intervention could prevent irreversible neuronal loss
Translation Potential
Score: 9/10
Therapeutic: Direct path to clinical trial for lead compounds
Biomarker: Aggregate reduction as surrogate endpoint
Platform: Expandable to other polyQ diseases
Cross-References
[Spinocerebellar Ataxia Type 1](/diseases/spinocerebellar-ataxia-type-1) — ATXN1 gene, CAG repeat
[Spinocerebellar Ataxia Type 2](/diseases/spinocerebellar-ataxia-type-2) — ATXN2 gene, CAG repeat
[Spinocerebellar Ataxia Type 3 (SCA3/MJD)](/diseases/spinocerebellar-ataxia-type-3) — ATXN3 gene, most common
[Spinocerebellar Ataxia Type 6](/diseases/spinocerebellar-ataxia-type-6) — CACNA1A gene
[Spinocerebellar Ataxia Type 7](/diseases/spinocerebellar-ataxia-type-7) — ATXN7 gene
The following diagram shows the key molecular relationships involving Spinocerebellar Ataxia (SCA) Disease-Modifying Therapy Development discovered through SciDEX knowledge graph analysis: